Drug
Trastuzumab (or biosimilar)
Trastuzumab (or biosimilar) is a pharmaceutical drug with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
recruiting375%
not_yet_recruiting125%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_2
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
NCT07220135
recruitingphase_2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331
recruitingphase_2
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
NCT07393425
not_yet_recruitingphase_2
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
NCT07246317
Clinical Trials (4)
Showing 4 of 4 trials
NCT07220135Phase 2
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
NCT06649331Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT07393425Phase 2
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
NCT07246317Phase 2
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4